Get started
SUN PHARMACEUTICAL IND LSS

SUN PHARMACEUTICAL IND L

1,666.40INRR
−17.00−1.01%
At close at 10:28 GMT
INR
No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Forecast Seasonals Options

SUNPHARMA fundamentals

Key facts

Market capitalization‪4.04 T‬INR
Dividend yield (indicated)0.90%
Price to earnings Ratio (TTM)36.92
Basic EPS (TTM)45.59INR
Founded1983
Employees (FY)—
CEODilip Shantilal Shanghvi
Websitesunpharma.com
About

Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. It offers tablets, capsules, injectable, inhalers, ointments, creams, and liquids. The company was founded by Dilip Shantilal Shanghvi in 1983 and is headquartered in Mumbai, India.

Ownership
‪‪2.40 B‬‬
Closely held shares
‪‪1.41 B‬‬ (58.69%)
Free Float shares
‪‪991.08 M‬‬ (41.31%)
Closely held shares
‪‪1.41 B‬‬ (58.69%)
Free Float shares
‪‪991.08 M‬‬ (41.31%)
Capital structure
Market cap
‪‪4.04 T‬‬
Debt
‪‪23.62 B‬‬
Minority interest
‪‪2.68 B‬‬
Cash & equivalents
‪‪249.88 B‬‬
Enterprise value
‪‪3.82 T‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪4.04 T‬‬
Price to earning ratio (P/E)
36.92x
Price to sales ratio (P/S)
—
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
36.92x
Price to sales ratio (P/S)
—
Valuation ratios
‪0.00‬
‪2.50‬
‪5.00‬
‪7.50‬
‪10.00‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪11.00‬
‪22.00‬
‪33.00‬
‪44.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪15%‬
‪17%‬
‪19%‬
‪21%‬
‪23%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪40.00 B‬‬
‪‪80.00 B‬‬
‪‪120.00 B‬‬
‪‪160.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪35.00 B‬‬
‪‪70.00 B‬‬
‪‪105.00 B‬‬
‪‪140.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪35.00 B‬‬
‪‪70.00 B‬‬
‪‪105.00 B‬‬
‪‪140.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Pharmaceutical
By country
Period: 2024
United States
India
Emerging Markets
Rest of the World

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪40.00 B‬‬
‪‪80.00 B‬‬
‪‪120.00 B‬‬
‪‪160.00 B‬‬
Actual
Estimate
Earnings
Next:Jul 31, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪3.50‬
‪7.00‬
‪10.50‬
‪14.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
35.10%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
0.92%
Next payment
5.50
Next ex-date
Jul 7, 2025
Next pay date
Aug 8, 2025
Dividend history
‪0.80%‬
‪0.92%‬
‪1.04%‬
‪1.16%‬
‪1.28%‬
2020
2021
2022
2023
2024
‪0.00‬
‪4.00‬
‪8.00‬
‪12.00‬
‪16.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪30.00 B‬‬
‪‪60.00 B‬‬
‪‪90.00 B‬‬
‪‪120.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪150.00 B‬‬
‪‪300.00 B‬‬
‪‪450.00 B‬‬
‪‪600.00 B‬‬
Assets
Liabilities